Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices 71889 

Controlled substance Drug code Schedule 

ortho-Fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)isobutyramide) ................................... 9853 I 

Para-Fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1- phenethylpiperidin-4-yl)furan-2-carboxamide) ............................ 9854 I 

2′-Fluoro ortho-fluorofentanyl (N-(1-(2- fluorophenethyl)piperidin-4-yl)-N-(2- fluorophenyl)propionamide; also known 

as 2′-fluoro 2- fluorofentanyl).

9855 I 

beta-Methyl fentanyl (N-phenyl-N-(1-(2- phenylpropyl)piperidin-4-yl)propionamide; also known as b-methyl fentanyl) .. 9856 I 

Amphetamine ..................................................................................................................................................................... 1100 II 

Methamphetamine ............................................................................................................................................................. 1105 II 

Lisdexamfetamine .............................................................................................................................................................. 1205 II 

Phenmetrazine ................................................................................................................................................................... 1631 II 

Methylphenidate ................................................................................................................................................................. 1724 II 

Amobarbital ........................................................................................................................................................................ 2125 II 

Pentobarbital ...................................................................................................................................................................... 2270 II 

Secobarbital ....................................................................................................................................................................... 2315 II 

Glutethimide ....................................................................................................................................................................... 2550 II 

1-Phenylcyclohexylamine .................................................................................................................................................. 7460 II 

Phencyclidine ..................................................................................................................................................................... 7471 II 

ANPP (4-Anilino-N-phenethyl-4-piperidine) ....................................................................................................................... 8333 II 

Norfentanyl (N-phenyl-N-(piperidin-4-yl) propionamide) .................................................................................................... 8366 II 

Phenylacetone ................................................................................................................................................................... 8501 II 

1-Piperidinocyclohexanecarbonitrile .................................................................................................................................. 8603 II 

Cocaine .............................................................................................................................................................................. 9041 II 

Codeine .............................................................................................................................................................................. 9050 II 

Etorphine HCl .................................................................................................................................................................... 9059 II 

Dihydrocodeine .................................................................................................................................................................. 9120 II 

Oxycodone ......................................................................................................................................................................... 9143 II 

Hydromorphone ................................................................................................................................................................. 9150 II 

Ecgonine ............................................................................................................................................................................ 9180 II 

Ethylmorphine .................................................................................................................................................................... 9190 II 

Hydrocodone ...................................................................................................................................................................... 9193 II 

Levomethorphan ................................................................................................................................................................ 9210 II 

Levorphanol ....................................................................................................................................................................... 9220 II 

Isomethadone .................................................................................................................................................................... 9226 II 

Meperidine ......................................................................................................................................................................... 9230 II 

Meperidine intermediate-B ................................................................................................................................................. 9233 II 

Oliceridine (N-[(3-methoxythiophen-2yl)methyl] ({2-[9r)-9-(pyridin-2-yl)-6-oxaspiro[4.5] decan-9-yl] ethyl {time})amine 

fumarate).

9245 II 

Methadone ......................................................................................................................................................................... 9250 II 

Dextropropoxyphene, bulk (non-dosage forms) ................................................................................................................ 9273 II 

Morphine ............................................................................................................................................................................ 9300 II 

Thebaine ............................................................................................................................................................................ 9333 II 

Oxymorphone .................................................................................................................................................................... 9652 II 

Noroxymorphone ............................................................................................................................................................... 9668 II 

Thiafentanil ........................................................................................................................................................................ 9729 II 

Alfentanil ............................................................................................................................................................................ 9737 II 

Remifentanil ....................................................................................................................................................................... 9739 II 

Sufentanil ........................................................................................................................................................................... 9740 II 

Carfentanil .......................................................................................................................................................................... 9743 II 

Tapentadol ......................................................................................................................................................................... 9780 II 

Fentanyl ............................................................................................................................................................................. 9801 II 

The company plans to bulk 

manufacture the listed controlled 

substances for forensic purposes, to 

research analytical reference standards 

and as Active Pharmaceutical 

Ingredients for Phase 1 trials. In 

reference to drug codes 7360 

(Marihuana), and 7370 

(Tetrahydrocannabinols), the company 

plans to bulk manufacture these drugs 

as synthetic. No other activities for these 

drug codes are authorized for this 

registration. 

Claude Redd, 

Acting Deputy Assistant Administrator. 

[FR Doc. 2023–22954 Filed 10–17–23; 8:45 am] 

BILLING CODE P 

OFFICE OF THE DIRECTOR OF 

NATIONAL INTELLIGENCE 

Notice of Meeting: National Intelligence 

University Board of Visitors 

AGENCY: National Intelligence 

University (NIU), Office of the Director 

of National Intelligence (ODNI). 

ACTION: Notice of Federal advisory 

committee meeting of the National 

Intelligence University Board of 

Visitors. 

SUMMARY: ODNI is publishing this 

notice to announce that the following 

Federal advisory committee meeting of 

the NIU Board of Visitors (BoV) will 

take place. This meeting is closed to the 

public. 

DATES: Wednesday, 25 October, 2023, 

8:30 a.m. to 3:00 p.m., and Thursday, 26 

October, 8:30 a.m. to 1 p.m., Bethesda, 

MD. 

ADDRESSES: National Intelligence 

University, 4600 Sangamore Road, 

Bethesda, MD 20816. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Patricia ‘‘Patty’’ Larsen, Designated 

Federal Officer, (301) 243–2118 (Voice), 

excom@odni.gov (email). Mailing 

address is National Intelligence 

University, Roberdeau Hall, 

Washington, DC 20511. Website: http:// 

ni-u.edu/wp/about-niu/leadership-2/ 

board-of-visitors/. 

SUPPLEMENTARY INFORMATION: This 

meeting is being held under the 

provisions of the Federal Advisory 


ddrumheller on DSK120RN23PROD with NOTICES1
71890 Federal Register / Vol. 88, No. 200 / Wednesday, October 18, 2023 / Notices 

Committee Act of 1972 (5 U.S.C. 1001– 

1014), the Government in the Sunshine 

Act of 1976 (5 U.S.C. 552b), and 41 CFR 

102–3.140 and 102–3.150. The meeting 

includes the discussion of classified 

information and classified materials 

regarding intelligence education issues, 

internal personnel rules and practices of 

NIU, and pre-decisional strategic 

planning matters; and the Director of 

National Intelligence, or her designee, in 

consultation with the ODNI Office of 

General Counsel, has determined the 

meeting will be closed to the public 

under the exemptions set forth in 5 

U.S.C. 552b(c)(1),552b(c)(2), and 

552b(c)(9)(B). 

I. Purpose of the Meeting: The Board 

will discuss and provide written 

observations and recommendations on 

matters relating to NIU personnel, 

budget, facilities, strategic planning, 

information technology, intelligence 

programs, subcommittee read-outs, and 

whole of institution assessment data, as 

well as discuss current classified 

intelligence education issues. 

II. Agenda: Welcome and Call to 

Order; President State of the University; 

Resources—Strategic Planning; Break 

for Lunch; Resources—Budget, 

Information Technology, Personnel, 

Whole of Institution Assessment Data 

(End of Day 1). Welcome and Call to 

Order; Subcommittee Preparatory and 

Administrative Meetings; Governance 

and Strategic Planning Subcommittee 

Meeting; NIU Board of Visitors 

Executive Session (End of Day 2). 

III. Meeting Accessibility: The public 

or interested organizations may submit 

written statements to the NIU BoV about 

its mission and functions. Written 

statements may be submitted at any 

time or in response to the stated agenda 

of a planned meeting of the NIU BoV. 

IV. Written Statements: All written 

statements shall be submitted to the 

Designated Federal Officer for the NIU 

BoV, and this individual will ensure 

that the written statements are provided 

to the membership for their 

consideration. 

Robert A. Newton, 

Committee Management Officer and Deputy 

Chief Operating Officer. 

[FR Doc. 2023–22967 Filed 10–17–23; 8:45 am] 

BILLING CODE P 

NEIGHBORHOOD REINVESTMENT 

CORPORATION 

Sunshine Act Meetings 

TIME AND DATE: 2 p.m., Thursday, 

October 19, 2023. 

PLACE: 1255 Union Street NE, Suite 500, 

Washington, DC 20002. 

STATUS: Parts of this meeting will be 

open to the public. The rest of the 

meeting will be closed to the public. 

MATTERS TO BE CONSIDERED: Regular 

Board of Directors meeting. 

The Interim General Counsel of the 

Corporation has certified that in her 

opinion, one or more of the exemptions 

set forth in the Government in the 

Sunshine Act, 5 U.S.C. 552b(c)(2) and 

(4) permit closure of the following 

portion(s) of this meeting: 

• Executive (Closed) Session 

Agenda 

I. Call to Order 

II. Sunshine Act Approval of Executive 

(Closed) Session 

III. Executive Session: Report from CEO 

IV. Executive Session: Report from CFO 

V. Executive Session: GAO Workplan 

Update 

VI. Executive Session: Report from 

Interim General Counsel 

VII. Executive Session: Report from CIO 

VIII. Executive Session: NeighborWorks 

Compass Update 

IX. Action Item: Approval of Meeting 

Minutes—August 3 Special Audit 

Committee Meeting and August 17 

Annual Board of Directors Meeting 

X. Action Item: Professional Learning 

and Event Management System 

(PLEMS) 

XI. Action Item: Atlanta Office Lease 

XII. Discussion Item: October 2 Audit 

Committee Meeting 

XIII. Discussion Item: National 

NeighborWorks Association 

Presentation 

XIV. Discussion Item: Capital 

Corporations Leadership 

a. Community Housing Capital 

b. NeighborWorks Capital 

XV. Inflation Reduction Act Update 

XVI. FY2024 Corporate Scorecard 

XVII. Management Program Background 

and Updates Other Reports 

a. 2023 Board Calendar 

b. 2023 Board Agenda Planner 

c. CFO Report 

i. Financials (through 7/31/23) 

ii. Single Invoice Approvals $100K 

and over 

iii. Vendor Payments $350K and over 

iv. Exceptions 

d. Programs Dashboard 

e. Housing Stability Counseling 

Program (HSCP) 

f. Strategic Plan Scorecard—FY23 Q3 

(Q3 Production) 

PORTIONS OPEN TO THE PUBLIC: 

Everything except the Executive 

(Closed) Session. 

PORTIONS CLOSED TO THE PUBLIC: 

Executive (Closed) Session. 

CONTACT PERSON FOR MORE INFORMATION: 

Jenna Sylvester, Paralegal, (202) 568– 

2560; jsylvester@nw.org. 

Jenna Sylvester, 

Paralegal. 

[FR Doc. 2023–23046 Filed 10–16–23; 11:15 am] 

BILLING CODE P 

POSTAL REGULATORY COMMISSION 

[Docket Nos. MC2024–7 and CP2024–7; 

MC2024–8 and CP2024–8; MC2024–9 and 

CP2024–9; MC2024–10 and CP2024–10] 

New Postal Products 

AGENCY: Postal Regulatory Commission. 

ACTION: Notice. 

SUMMARY: The Commission is noticing a 

recent Postal Service filing for the 

Commission’s consideration concerning 

a negotiated service agreement. This 

notice informs the public of the filing, 

invites public comment, and takes other 

administrative steps. 

DATES: Comments are due: October 20, 

2023. 

ADDRESSES: Submit comments 

electronically via the Commission’s 

Filing Online system at http://

www.prc.gov. Those who cannot submit 

comments electronically should contact 

the person identified in the FOR FURTHER

INFORMATION CONTACT section by 

telephone for advice on filing 

alternatives. 

FOR FURTHER INFORMATION CONTACT: 

David A. Trissell, General Counsel, at 

202–789–6820. 

SUPPLEMENTARY INFORMATION: 

Table of Contents 

I. Introduction 

II. Docketed Proceeding(s) 

I. Introduction 

The Commission gives notice that the 

Postal Service filed request(s) for the 

Commission to consider matters related 

to negotiated service agreement(s). The 

request(s) may propose the addition or 

removal of a negotiated service 

agreement from the Market Dominant or 

the Competitive product list, or the 

modification of an existing product 

currently appearing on the Market 

Dominant or the Competitive product 

list. 

Section II identifies the docket 

number(s) associated with each Postal 

Service request, the title of each Postal 

Service request, the request’s acceptance 

date, and the authority cited by the 

Postal Service for each request. For each 

request, the Commission appoints an 

officer of the Commission to represent 


ddrumheller on DSK120RN23PROD with NOTICES1